Zurück
HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
HCID 1102Erstellt: 24. Oktober 2026

4-Azaoctamethylendiamin

SperMidin · N1-(3-AMINOPROPYL)BUTANE-1,4-DIAMINE · Spermidine-Rich Wheat Germ Extract · Spermidine,99% · SPERMIDINE FREE BASE · 1,4-Butanediamine, N-(3-aminopropyl)- · 3.2 Kg · Spermidie

https://huagongshe.com/de/chemical/1102

Molekülstruktur von 4-Azaoctamethylendiamin

Identifikatoren & physikalische Daten

CAS No.124-20-9
SummenformelC7H19N3
Durchschnittliche Molmasse145,25 g/mol
Monoisotopische Masse145,15789761 g/mol
SMILESNCCCCNCCCN
InChIKeyATHGHQPFGPMSJY-UHFFFAOYSA-N
PubChem CID1102
ChEMBLCHEMBL19612
ChEBICHEBI:16610
EC No.204-689-0
DTXSIDDTXSID4036645
Lokaler Name4-Azaoctamethylendiamin

Chemische & physikalische Eigenschaften

XLogP-1
Polarare Oberfläche (TPSA)64,1
H-Brücken-Donoren3
H-Brücken-Akzeptoren3
Frei drehbare Bindungen7
Schwere Atome10
Formalladung0
Komplexität56,8
ArzneimittelPharmaceuticals -> Listed in ZINC15
DuftstoffeFragrance Ingredient (1,4-Butanediamine, N-(3-aminopropyl)-) -> IFRA transparency List
Schmelzpunkt< 25 °C23-25 °C
Physical DescriptionSolid
Collision Cross Section136.5 Ų [M+Na]+ [CCS Type: DTMethod: single field calibrated with ESI Low Concentration Tuning Mix (Agilent)]131.9 Ų [M+H]+ [CCS Type: DTMethod: single field calibrated with Agilent tune mix (Agilent)]136.2 Ų [M+Na]+
Siedepunkt128-130 °C (14 mmHg)
Dichte1.00 g/mL at 20 °C
Brechungsindexn20/D 1.479(lit.)
Flammpunkt>230 °F
Lagerbedingungenroom temp
LöslichkeitH2O: 1 M at 20 °C, clear, colorlessMiscible with water, ethanol and ether.
AggregatzustandLiquid After Melting
pKa (Säurekonstante)10.53±0.19(Predicted)
FarbeClear colorless
Wichte0.925
pH12.0-13.5 (25℃, 1M in H2O)
GeruchIchtyal, ammoniacal
Biologische Quellesynthetic
Merck14,8742
BRN1698591
StabilitätStable, but air-sensitive and very hygroscopic - store under argon. Incompatible with acids, acid chlorides, acid anhydrides, oxidizing agents.
Kosmetik-Inhaltsstoffe FunktionenANTIOXIDANTHAIR CONDITIONING
InChI1S/C7H19N3/c8-4-1-2-6-10-7-3-5-9/h10H,1-9H2
InChIKeyATHGHQPFGPMSJY-UHFFFAOYSA-N
SMILESNCCCCNCCCN
CAS Datenbank124-20-9(CAS DataBase Reference)
EPA chemische Informationen1,4-Butanediamine, N-(3-aminopropyl)- (124-20-9)

Sicherheit & Vorschriften

GHS-EinstufungDangerH314 (100%): Causes severe skin burns and eye damage [Danger Skin corrosion/irritation]P260, P264, P264+P265, P280, P301+P330+P331, P302+P361+P354, P304+P340, P305+P354+P338, P316, P317, P321, P363, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 83 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Regulatorische InformationenSpermidine: Does not have an individual approval but may be used under an appropriate group standard
Hazard Classes and CategoriesSkin Corr. 1A (100%)
TreatmentKidney dialysis is usually needed to relieve the symptoms of uremic syndrome until normal kidney function can be restored.
Gesundheitliche AuswirkungenChronic exposure to uremic toxins can lead to a number of conditions including renal damage, chronic kidney disease and cardiovascular disease.
ExpositionspfadeEndogenous, Ingestion, Dermal (contact)
ToxizitätsübersichtUremic toxins such as spermidine are actively transported into the kidneys via organic ion transporters (especially OAT3). Increased levels of uremic toxins can stimulate the production of reactive oxygen species. This seems to be mediated by the direct binding or inhibition by uremic toxins of the enzyme NADPH oxidase (especially NOX4 which is abundant in the kidneys and heart) (A7868). Reactive oxygen species can induce several different DNA methyltransferases (DNMTs) which are involved in the silencing of a protein known as KLOTHO. KLOTHO has been identified as having important roles in anti-aging, mineral metabolism, and vitamin D metabolism. A number of studies have indicated that KLOTHO mRNA and protein levels are reduced during acute or chronic kidney diseases in response to high local levels of reactive oxygen species (A7869).
Signs and SymptomsAs a uremic toxin, this compound can cause uremic syndrome. Uremic syndrome may affect any part of the body and can cause nausea, vomiting, loss of appetite, and weight loss. It can also cause changes in mental status, such as confusion, reduced awareness, agitation, psychosis, seizures, and coma. Abnormal bleeding, such as bleeding spontaneously or profusely from a very minor injury can also occur. Heart problems, such as an irregular heartbeat, inflammation in the sac that surrounds the heart (pericarditis), and increased pressure on the heart can be seen in patients with uremic syndrome. Shortness of breath from fluid buildup in the space between the lungs and the chest wall (pleural effusion) can also be present.
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
F3-10-34
Wassergefährdungsklasse (WGK)3
TSCA-Inventar-StatusTSCA listed
UN-TransportnummerUN 2735 8/PG 2
Zollcode29212900
RTECS-Nr.EJ7000000
R-Sätze (R)34
GefahrensymboleC
Sicherheitshinweise (S)26-36/37/39-45-27
Gefahrenklasse8Eye Dam. 1Skin Corr. 1B
VerpackungsgruppeIII
Lagerklasse8A - Combustible corrosive hazardous materials

Anwendungen & Verwendung

Beschreibung

Spermidine is an endogenous polyamine. It is formed from putrescine by spermidine synthase.

Herstellung & Synthese

synthetische

The linker resin 2 was used in the synthesis of spermidine. In order to initiate the preparation the 2-nitrossulfonamide was anchored on the resin 2 by reaction in THF under reflux. The resulting resin 3 then reacted with 4-bromobutylphthalimide in acetonitrile in the presence of Cs2CO3 as base, generating the resin 4. Protected spermidine 5 was cleaved from resin 4 after treatment with hydrate hydrazine at room temperature. Spermidine 5 was previously prepared by our group in solution system utilizing Fukuyama's sulfonamide.Synthesis and Characterization of a Linker for Primary Amines used in the Solid Phase Organic Synthesis of SpermidineJ. Braz. Chem. Soc., Vol. 22, No. 1, 86-91, 2011DOI: 10.1590/S0103-50532011000100011